Key insights
- The article expresses frustration over Novo Nordisk's (NVO) stock performance, which has only risen 1.25% in five years despite market leadership in GLP-1 medications. The author questions management's effectiveness, suggesting poor financial management or excessive executive compensation as potential reasons for the lackluster stock returns, especially given the demand for their products. The company's stock is noted to be down 4% on the day of the article.
I’m genuinely dumbfounded how you can be first to market at an injectable GLP-1, have tons of patients taking it, get first to market with the best oral GLP-1 with thousands of prescriptions for it… and still be only up 1.25% from 5 years ago before your GLP-1 medications were even released.
Like how bad must the upper level management be? Are they just hemorrhaging money or paying out crazy salaries to their upper level c-suite?
Again, developing one of the biggest breakthroughs in modern medicine and yet only being up 1.25% in five years… is nuts. Sure, the IV injectable isn’t as good as LLY. But the oral medication is best in its class and has a huge market and demand for patients across the world.
It’s down 4% today and I just can’t wrap my head around how this company isn’t printing money aside from just horrible, horrible, upper level management or frankly fraud at the upper levels. End rant.